Why invest in Hofseth BioCare?

A strong ESG-profile, and patented processes coupled with world class R&D with diversified pipelines including research programs on asthma, COVID-19 and gastro

Ticker: HBC
Last updated: 23.09.2020 11:18
Latest

8.10 NOK

Change

0.02

Change (%)

0.25

Share information

IR contact

News

Reports

Governance

OVI 3832 01
LATEST REPORT

Q2 2020 Report

Download our latest report, or view all quarterly and yearly reports in the archives.

Download Q2 2020
All reports
16:9
NEXT UP

Financial calendar

Q3 Quarterly report 2020
30.10.2020

Q4 Quarterly report 2020
05.02.2021

Stock exchange notices

View all notices

SHARE CAPITAL INCREASE REGISTERED

18.09.2020

New study highlights the potential of OmeGo® as a prophylactic therapy for Asthma and COPD

01.09.2020

ISSUANCE OF NEW SHARES FOLLOWING EXERCISE OF OPTIONS – PRIMARY INSIDER DISCLOSURE

28.08.2020

SECOND QUARTER & HALF YEAR 2020 FINANCIAL REPORT

28.08.2020

SECURES DISTRIBUTION WITH A GLOBAL RETAILER GIANT IN THE UK, SPAIN, ICELAND, AND ONLINE FOR BRILLIANT SALMON OIL™ FOR PETS

27.08.2020

Contact investor relations

James Berger
James Berger
Head of Investor Relations & Strategy
+41 79 950 10 34 jb@hofsethbiocare.no
Crawford Currie
Dr. Crawford Currie
Medical R&D & Investor Relations
+44 7968 195497 cc@hofsethbiocare.no